Endocrinology Medical News about energy expenditure

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions
International Journal of Obesity, 07/20/09

Fong TM et al. – Rimonabant and taranabant are two extensively studied cannabinoid–1 receptor (CB1R) inverse agonists. Their effects on in vivo peripheral tissue metabolism are generally well replicated. The central nervous system site of action of taranabant or rimonabant is firmly established based on brain receptor occupancy studies. At the whole–body level, the mechanism of action of CB1R inverse agonists includes a reduction in food intake and an increase in energy expenditure.

<< Previous
Relationship of PPARgamma2 Polymorphism with Obesity and...

Next >>
Changes in Growth Hormone and Insulin-like Growth Factor-I Levels...